- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02225210
Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients
24. august 2014 opdateret af: Shuaiya, Fuling Central Hospital of Chongqing City
Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients -a Single Center,Randomized and Controlled Trial
This study was designed to observe the effects of dexmedetomidine on delirium and haemodynamic in mechanical ventilated elderly patients,and to evaluate the safety of dexmedetomidine.
Studieoversigt
Status
Ukendt
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
80
Fase
- Fase 4
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
60 år til 80 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Written informed consent
- Intensive care unit patients who need mechanical ventilation
- Anticipate duration of mechanical ventilation longer than 24 hours,and shorter than 96 hours prior to giving investigational products
- Acute physiology and chronic health evaluation II score more than 10
- Aged between 60 to 80 years old
- Weight between plus or minus 20% of the standard weight. Male: (height cm - 80) × 70% = standard weight Female: (height cm - 70) × 60% = standard weight
Exclusion Criteria:
- Trauma and burn patients
- Any kind of dialysis
- Suspected or confirmed difficult airway
- Use of neuromuscular blocking drugs(Except using for intubation )
- Neuromuscular disease
- Epidural or subarachnoid anesthesia
- Plan to give general anesthesia before 24 hours drugs intervention or after giving investigational drugs
- Serious central nervous system disease
- Mental disability or mental disease
- Acute hepatitis and serious liver disease(Child-Pugh C)
- Unstable angina and acute myocardium infarction
- Left ventricular ejection volume less than 30%,heart rate less than 50 beats per minute
- II and III degree atrioventricular block
- Systolic pressure less than 90 mmHg after giving vasopressors twice before beginning of this study
- Consciousness disturbance patients whose blood pressure less than 70mmHg and blood lactate more than 4.0mmol/L
- Suspected or confirmed long term use of narcotic analgesics
- Subjects who are breastfeeding or pregnant
- Allergic to investigational products or with other contraindication
- Participated in other study within 30 days
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group dexmedetomidine ,dexmedetomidine
Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1
for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
|
Loading dose:0.4μg.kg-1
Maintenance dose :0.2~0.7µg.kg-1
Sedation-Agitation Scale: maintain between 3 and 4.
|
|
Aktiv komparator: Group midazolam,midazolam,fentanyl
Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1
and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1
and fentanyl 0.5~1μg.kg-1.h-1
separately.
|
Loading dose of midazolam:0.1mg.kg-1 .
Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 .
Sedation-Agitation Scale: maintain between 3 and 4
Loading dose of fentanyl:1 μg.kg-1 .
Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 .
Sedation-Agitation Scale: maintain between 3 and 4
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Changes in blood pressure within 48 hours after drug intervention
Tidsramme: Within 48 hours after drug intervention
|
Within 48 hours after drug intervention
|
|
Number of Participants with blood pressure decrease more than 20% of the baseline value or systolic pressure less than 100 mmHg
Tidsramme: within 48 hours afer drug intervention
|
within 48 hours afer drug intervention
|
|
The number of cases who develop delirium
Tidsramme: Within 48 hours after drug intervention
|
Within 48 hours after drug intervention
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Changes in heart rate
Tidsramme: Within 48 hours after drug intervention
|
Within 48 hours after drug intervention
|
|
Changes in respiratory rate
Tidsramme: Within 48 hours after drug intervention
|
Within 48 hours after drug intervention
|
|
Changes in central venous pressure
Tidsramme: Within 48 hours after drug intervention
|
Within 48 hours after drug intervention
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. september 2014
Primær færdiggørelse (Forventet)
1. juni 2015
Studieafslutning (Forventet)
1. juli 2015
Datoer for studieregistrering
Først indsendt
22. august 2014
Først indsendt, der opfyldte QC-kriterier
24. august 2014
Først opslået (Skøn)
26. august 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
26. august 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. august 2014
Sidst verificeret
1. august 2014
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Sygdomme i nervesystemet
- Neurologiske manifestationer
- Forvirring
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Delirium
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Bedøvelsesmidler, intravenøst
- Bedøvelsesmidler, general
- Bedøvelsesmidler
- Analgetika, ikke-narkotisk
- Adrenerge alfa-2-receptoragonister
- Adrenerge alfa-agonister
- Adrenerge agonister
- Analgetika, Opioid
- Narkotika
- Beroligende midler
- Psykotropiske stoffer
- Hypnotika og beroligende midler
- Adjuvanser, anæstesi
- Anti-angst midler
- GABA modulatorer
- GABA agenter
- Fentanyl
- Midazolam
- Dexmedetomidin
Andre undersøgelses-id-numre
- Shu 2014
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Safety of Dexmedetomidine Sedation
-
Columbia UniversityBaylor College of Medicine; University of Pittsburgh; Boston Children's Hospital og andre samarbejdspartnereAfsluttetSedation | DexmedetomidinForenede Stater
-
Peking UniversityAfsluttetDexmedetomidin | Dyb SedationKina
-
Dayton VA Medical CenterAfsluttetSedation | Dexmedetomidin | KOLForenede Stater
-
PfizerAfsluttetSedation | Gastrointestinal endoskopi | DexmedetomidinKorea, Republikken
-
Tanta UniversityAfsluttetSedation | Dexmedetomidin | Propofol | Midazolam | Double-J Ureteral StentEgypten
-
Brugmann University HospitalRekrutteringMR | Dexmedetomidin | Midazolam | Pædiatrisk SedationBelgien
-
Shiyou WeiShanghai East Hospital of Tongji UniversityAfsluttetSprays | Dexmedetomidin inducerede sedation | NæseadministrationKina
-
Sichuan Provincial People's HospitalIkke rekrutterer endnuSedation | Dexmedetomidin | Præanæstesisk medicin | Sikkerhed | Overvåget Anæstesiomsorg
-
Kafrelsheikh UniversityAfsluttetSedation | Dexmedetomidin | EBUS Guidet Transbronchial Needle AspirationEgypten
-
Anqing Municipal HospitalAfsluttetDexmedetomidin | Lidokain | Quality of Recovery (QoR-40), præoperativ og postoperativKina
Kliniske forsøg med Dexmedetomidine
-
Bahria International HospitalAfsluttet
-
Cairo UniversityRekrutteringBupivacain | Intratekal dexmedetomidin | Knæ-ortopædisk kirurgiEgypten
-
Peking University First HospitalRekrutteringDelirium | Dexmedetomidin | Postoperativ pleje | Intensivafdeling | Ældre patienter | EsketaminKina
-
Indonesia UniversityAfsluttetKnækirurgi | Bækkenkirurgi | Spinal anæstesiIndonesien
-
McGill University Health Centre/Research Institute...RekrutteringAnalgesi | Smerter, Akut | Nerveblok | Øvre ekstremitetskirurgiCanada
-
Benha UniversityRekrutteringDelirium - PostoperativtEgypten
-
Al-Azhar UniversityBenha UniversityIkke rekrutterer endnuPost-spinal rystenEgypten
-
Sichuan Academy of Medical SciencesIkke rekrutterer endnuSepsis | Septisk chok
-
Younes Ahmed YounesIkke rekrutterer endnu
-
Cairo UniversityUkendtSpinal anæstesi VarighedEgypten